Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001193125-25-065600
Filing Date
2025-03-27
Accepted
2025-03-27 17:01:43
Documents
5
Effectiveness Date
2025-03-27

Document Format Files

Seq Description Document Type Size
1 S-8 d928021ds8.htm S-8 48338
2 EX-5.1 d928021dex51.htm EX-5.1 6657
3 EX-23.1 d928021dex231.htm EX-23.1 1795
4 EX-FILING FEES d928021dexfilingfees.htm EX-FILING FEES 25857
5 GRAPHIC g928021g0327004626842.jpg GRAPHIC 2630
  Complete submission text file 0001193125-25-065600.txt   87498
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286182 | Film No.: 25780307
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)